Aldose reductase inhibitor
From Wikipedia, the free encyclopedia
Aldose reductase inhibitors are a class of drugs being studied as a way to prevent eye and nerve damage in people with diabetes. Their target, Aldose reductase, is an enzyme that is normally present in many other parts of the body, and catalizes one of the steps in the sorbitol(polyol)pathway that is responsible for fructose formation from glucose. Aldose reductase activity increases as glucose concentration rise in diabetes in those tissue that are not insulin sensitive , ie , the lens (anatomy), peripheral nerve and glomerulus. Sorbitol doesn't diffuse through cell membranes easily and therefore accumulates, causing osmotic damage which leads to retinopathy and neuropathy.
[edit] Diabetic Cataract
Diabetic cataract formation follows an increase in sugars in the lens. The excess sugar within the lens is reduced by aldose reductase to its alcohol, but the lens capsule is relatively impermeable to sugar alcohols. Because of the excess sugar alcohol (polyol), the lens imbibes water, causing osmotic imbalance. Eventually, increased sodium and decreased potassium levels and decrease glutathione levels lead to cataract formation. Topical administration of aldose reductase inhibitors have been shown to prevent the cataract in rats.[1]
[edit] References
- ^ Newell, FW. Opthalmology: Principles and Concepts, Fifth Edition. London: The CV Mosby Company, 1982, p. 332.
 |
This molecular or cell biology article is a stub. You can help Wikipedia by expanding it. |
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
